title: Comparison of clinical and pathological staging and long-term results of liver transplantation for hepatocellular carcinoma in a single transplant center.
abstract: Liver transplantation (OLT) is a treatment for hepatocellular carcinoma (HCC) superimposed on cirrhosis provided that the disease meets defined criteria. The aim of the study was to evaluate our experience with respect to clinical and pathological staging and long-term results. From 1996 to 2005, 50 patients underwent OLT for HCC including 43 men (86%) and seven women (14%) of median age 57 years (range 37 to 67). All patients fulfilled the Milan criteria. The HCC diagnosis was based on preoperative imaging and alpha-fetoprotein levels; no tumor biopsy was performed. Upon histological examination of the resected specimens, we discovered 6 (12%) incidentalomas and 8 (16%) cases of no HCC. Finally we had 42 "true" HCC. Twenty-six patients (52%) have been downstaged and 10 (20%) upstaged by preoperative imaging; 15% were pT1, 45% were pT2, 27% pT3, and 13% pT4a. Twenty-six percent of cases exceeded the Milan criteria. One patient (pT4a) with microvascular invasion died of pulmonary metastases at 14 months after transplantation. No HCC recurrences within the liver have been encountered at a median follow-up of 20 months (range 0 to 80 months). Overall the estimated 1-, 3-, and 5-year survival rates were 83%, 77%, and 72%, respectively. One-, 3-, and 5-year estimated survival rates were 87%, 75%, and 75% for pT1, and pT2, and 75%, 67%, and 67% for pT3 and pT4a, respectively (P = .99). Based on our experience OLT for HCC has long-term results comparable to those without HCC despite the presence of a significant number of cases exceeding the Milan criteria upon pathological staging.
authors.affiliation: Department of Surgery and Transplantation, University Hospital Udine, Italy. umberto.baccarani@uniud.it
authors.forename: U
authors.initials: U
authors.lastname: Baccarani
authors.forename: G L
authors.initials: GL
authors.lastname: Adani
authors.forename: C
authors.initials: C
authors.lastname: Avellini
authors.forename: D
authors.initials: D
authors.lastname: Lorenzin
authors.forename: G
authors.initials: G
authors.lastname: Currò
authors.forename: A
authors.initials: A
authors.lastname: Beltrami
authors.forename: A
authors.initials: A
authors.lastname: Pasqualucci
authors.forename: V
authors.initials: V
authors.lastname: Bresadola
authors.forename: A
authors.initials: A
authors.lastname: Risaliti
authors.forename: P L
authors.initials: PL
authors.lastname: Viale
authors.forename: C A
authors.initials: CA
authors.lastname: Beltrami
authors.forename: F
authors.initials: F
authors.lastname: Bresadola
mesh_terms: D000328:Adult; D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000473:pathology / Q000601:surgery*; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000473:pathology / Q000601:surgery*; D016031:Liver Transplantation / Q000401:mortality / Q000473:pathology / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D012189:Retrospective Studies; D016896:Treatment Outcome